Half of patients with muscle-invasive bladder cancer worldwide may not receive curative-intent therapy. Elderly or frail patients are most affected by this unmet need. TAR-200 is a novel, intravesical drug delivery system that provides sustained, local release of gemcitabine into the bladder over a 21-day dosing cycle. The phase 1 TAR-200-103 study evaluated the safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who either refused or were unfit for curative-intent therapy.
Eligible patients had cT2-cT3bN0M0 urothelial carcinoma of the bladder. TAR-200 was inserted for 4 consecutive 21-day cycles over 84 days. The primary end points were safety and tolerability at 84 days. Secondary end points included rates of clinical complete response and partial response as determined by cystoscopy, biopsy, and imaging; duration of response; and overall survival.
Median age of the 35 enrolled patients was 84 years, and most were male (24/35, 68.6%). Treatment-emergent adverse events related to TAR-200 occurred in 15 patients. Two patients experienced treatment-emergent adverse events leading to removal of TAR-200. At 3 months, complete response and partial response rates were 31.4% (11/35) and 8.6% (3/35), respectively, yielding an overall response rate of 40.0% (14/35; 95% CI 23.9-57.9). Median overall survival and duration of response were 27.3 months (95% CI 10.1-not estimable) and 14 months (95% CI 10.6-22.7), respectively. Progression-free rate at 12 months was 70.5%.
TAR-200 was generally safe, well tolerated, and had beneficial preliminary efficacy in this elderly and frail cohort with limited treatment options.
The Journal of urology. 2023 Apr 07 [Epub]
Mark D Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir, Rian J Dickstein, Félix Guerrero-Ramos, Kristen R Scarpato, Jason M Hafron, Edward M Messing, Christopher J Cutie, John C Maffeo, Bradley Raybold, Albert Chau, Katharine A Stromberg, Kirk A Keegan
Mayo Clinic Arizona, Phoenix, Arizona., Urology Associates, Nashville, Tennessee., Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain., Fundacion Instituto Valenciano de Oncologia, Valencia, Spain., Chesapeake Urology, Baltimore, Maryland., University Hospital 12 de Octubre, Madrid, Spain., Vanderbilt University Medical Center, Nashville, Tennessee., Michigan Institute of Urology, Troy, Michigan., University of Rochester, Rochester, New York., Janssen Research & Development, Lexington, Massachusetts., Janssen Research & Development, Spring House, Pennsylvania., Datacision Limited, London, United Kingdom., Janssen Research & Development, Raritan, New Jersey.